Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Tarceva linked with two patient deaths
Two patients died following liver damage related to taking the cancer drug Tarceva, according to a letter the FDA posted. The two patients were involved in a study with 13 other patients that the companies believed had moderate liver problems, but it turns out the problems were severe. They died within one month of completing treatment. There were 36 participants in the study in total.
OSI Pharmaceuticals manufactures the medication, which aims to treat lung and pancreatic cancers. Its partner, Genentech, sells Tarceva.
As a result, the drug now has stronger liver toxicity warnings on its label. The companies sent a letter to physicians yesterday that emphasizes the importance of close monitoring of patients taking the drug if the patients have liver problems.
The FDA approved Tarceva in 2004.
- view the letter (.pdf)
- read the Business Week report
- see what News Day has to say
Related Articles:
Roche, Cipla trade jabs on Tarceva
Tarceva gets Japan's nod
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
